아스페르길루스증 치료 시장 : 유형, 약제 클래스, 약제 형태, 유통 채널별 - 세계 예측(2024-2032년)

Aspergillosis treatment market is anticipated to record 4.3% CAGR over 2024-2032, driven by a rise in Aspergillosis infections among immunocompromised individuals, such as those undergoing chemotherapy, organ transplants, or living with HIV/AIDS. According to the CDC, about 1-2% of organ transplant recipients develop Aspergillosis. Additionally, there is increasing prevalence of respiratory conditions like asthma and COPD, which affect over 25 million and 16 million Americans respectively. The aging population, more susceptible to infections due to weakened immune systems, further boosts demand for Aspergillosis treatments.

The development of new antifungal agents and improved diagnostic techniques has enhanced treatment efficacy and accuracy. Increased awareness and funding for fungal infection research have led to better treatment protocols and stronger healthcare infrastructure. Growing healthcare investments, particularly in emerging economies, are expected to further drive the market, ensuring wider access to advanced treatments and improving patient outcomes.

The overall Aspergillosis treatment industry is classified based on type, drug class, drug form, distribution channel, and region.

The corticosteroids drug class segment is poised to gain substantial traction through 2032 due to its effectiveness in managing inflammatory responses associated with the infection. Corticosteroids, such as prednisone and methylprednisolone, are commonly used to reduce inflammation and immune responses in patients with allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA). These drugs help alleviate symptoms such as wheezing, shortness of breath, and chest tightness, providing significant relief to patients. The increasing prevalence of respiratory conditions and the rising incidence of Aspergillosis are driving the demand for corticosteroids.

The injections segment will hold a notable market share by 2032, owing to the advantages it offers in terms of drug delivery and efficacy. Injectable formulations are preferred for their ability to deliver high doses of medication directly into the bloodstream, ensuring faster and more effective treatment of severe or systemic Aspergillosis infections. This route of administration is crucial for patients with severe fungal infections or those who cannot tolerate oral medications due to gastrointestinal issues or absorption problems. The growing emphasis on rapid and effective treatment options, coupled with advancements in injectable drug formulations, is driving the segment growth.

North American Aspergillosis treatment market size will expand at a rapid pace through 2032, driven by high prevalence rate of fungal infections, advanced healthcare infrastructure, and substantial research investments. The region's well-established healthcare systems and significant medical research capabilities facilitate the development and adoption of innovative treatment options. Additionally, the rising incidence of chronic respiratory diseases and immunocompromised conditions contributes to the increased demand for effective Aspergillosis therapies. Government initiatives and funding aimed at improving healthcare outcomes further bolster market growth across the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360°synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of aspergillosis
    • 3.2.1.2 Growing awareness of fungal infections
    • 3.2.1.3 Development of new antifungal agents
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited treatment options
    • 3.2.2.2 High treatment costs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Pricing analysis, 2023
  • 3.6.1 By region
  • 3.6.2 By key player
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Acute aspergillosis
• 5.3 Chronic aspergillosis

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Antifungal drugs
  • 6.2.1 Azoles
  • 6.2.2 Echinocandins
  • 6.2.3 Polyenes
  • 6.2.4 Allylamines
  • 6.2.5 Other antifungal drugs
• 6.3 Corticosteroids
  • 6.3.1 Prednisolone
  • 6.3.2 Prednisone
  • 6.3.3 Methylprednisolone
  • 6.3.4 Other corticosteroids
• 6.4 Other drug class

Chapter 7 Market Estimates and Forecast, By Drug Form, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
  • 7.2.1 Tablets
  • 7.2.2 Capsules
• 7.3 Injections
• 7.4 Ointments
• 7.5 Powders

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Astellas Pharma Inc.
• 10.3 Astra Zeneca PLC
• 10.4 Basilea Pharmaceutica Ltd.
• 10.5 Bayer AG
• 10.6 Endo International plc
• 10.7 F2G
• 10.8 GSK plc
• 10.9 Johnson & Johnson
• 10.10 Merck & Co., Inc.
• 10.11 Mayne Pharma Group Limited
• 10.12 Novartis AG
• 10.13 PULMATRiX, Inc.
• 10.14 Takeda Pharmaceutical Company Ltd.
• 10.15 Viatris Inc.